KM
Kenzie Maclsaac
Partner at Cure Ventures
Boston, Massachusetts
Overview
Kenzie Maclsaac is a Partner at Cure Ventures in Boston, Massachusetts, with a Ph.D. from MIT and expertise in biomarker discovery, statistical computing, and machine learning. With a background that includes senior roles at Bristol Myers Squibb and Novartis, Maclsaac has a proven track record in translational bioinformatics and a strong focus on investing in early-stage companies in the healthcare and biotech sectors in Boston/New England.
Work Experience
Partner
2022 - Current
Senior Director
2021 - 2022
Director, Translational Bioinformatics
2018 - 2021
Bristol-Myers Squibb engages in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceuticals.
Raised $23,580,000,000.00 from RA Capital Management, OUP (Osage University Partners), Aperture Venture Partners, Greg Bailey, Connecticut Innovations, Knoll Capital Management, Vivo Capital, Venrock, Litmore Capital and Carl Icahn.
Director of Translational Bioinformatics
2018 - 2018
Senior Investigator II - Bioinformatics
2014 - 2018
Associate Principal Scientist
2009 - 2014
Genomics and target discovery for immunology and oncology drug discovery programs.
Merck is a biopharmaceutical company that offers medicines and vaccines for various diseases.
Raised $5,586,000.00 from Private Capital Advisors.
Research Affiliate
2009 - 2010